Hepatitis C : Screening, treatment and prevention Practical guidelines
| Journal | Volume 66 - 2003 |
| Issue | Fasc.1 - Expert Point of View |
| Author(s) | P. Michielsen, R. Brenard, N. Bourgeois, Ch. De Galocsy, J. Delwaide, J. Henrion, Y. Horsmans, F. Nevens, H. Reynaert, G. Robaeys, D. Sprengers, H. Van Vlierberghe |
| Full article |
 VIEW FREE PDF |
| Steering Committee Belgian Association for the Study of the Liver. |
|
Hepatitis C is a major health problem worldwide. According to the WHO. there are an estimated 170 mil- lion people infected with hepatitis C virus (HCV) (1). In Belgium, the prevalence of hepatitis C is approximately 1% (2). Blood transfusion used to be a major risk factor for acquiring HCV infection before screening for anti- bodies to HCV in the early nineties (in Belgium : from 01.07.1990 on). Injection drug use is now the most fre- quently identified risk factor for acquiring this infection. Thirty seven to 98 % of the intravenous drug users are seropositive for HCV (3,4). |
|
© Acta Gastro-Enterologica Belgica. |
